We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-21.81%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$222M
AUM Growth
-$100M
Cap. Flow
-$21.8M
Cap. Flow %
-9.81%
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
TELA icon
TELA Bio
TELA
+$9.68M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.68M
3
CUTR
Cutera, Inc.
CUTR
+$7.8M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.98M
5
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
+$1.88M

Top Sells

Rank Stock Value
1
CMRX
Chimerix, Inc.
CMRX
+$14.4M
2
BCYC
Bicycle Therapeutics
BCYC
+$7.68M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.66M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$5.96M
5
CYTK icon
Cytokinetics
CYTK
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$824M
$2.27M 1.02%
325,000
– –
PRQR icon
27
ProQR Therapeutics
PRQR
$327M
$2.13M 0.96%
2,740,000
+315,000
+13% +$235K
URGN icon
28
UroGen Pharma
URGN
$2.22B
$1.96M 0.88%
+238,670
New +$1.64M
DNA icon
29
Ginkgo Bioworks
DNA
$489M
$1.94M 0.87%
20,375
-2,870
-12% -$350K
VSTM icon
30
Verastem
VSTM
$668M
$1.84M 0.83%
132,500
-61,250
-32% -$976K
LRMR icon
31
Larimar Therapeutics
LRMR
$421M
$1.83M 0.82%
932,814
-10,888
-1% -$32.2K
HYPR icon
32
Hyperfine
HYPR
$89.7M
$1.7M 0.77%
763,075
– –
RYTM icon
33
Rhythm Pharmaceuticals
RYTM
$7.75B
$1.5M 0.68%
+362,000
New +$1.98M
MODD icon
34
Modular Medical
MODD
$29.4M
$1.43M 0.64%
9,181
+311
+4% +$42.6K
IMPL
35
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$1.35M 0.61%
+144,642
New +$1.06M
LENZ
36
LENZ Therapeutics
LENZ
$151M
$1.26M 0.57%
65,714
+29,214
+80% +$651K
DERM icon
37
Journey Medical
DERM
$213M
$919K 0.41%
245,733
+178,733
+267% +$707K
NGNE icon
38
Neurogene
NGNE
$758M
$628K 0.28%
30,500
-9,000
-23% -$220K
MGNX icon
39
MacroGenics
MGNX
$260M
$614K 0.28%
208,300
-168,100
-45% -$884K
NPCE icon
40
Neuropace
NPCE
$485M
$446K 0.2%
+90,100
New +$595K
FMTX
41
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$404K 0.18%
+58,700
New +$412K
OPTN
42
DELISTED
OptiNose
OPTN
$333K 0.15%
+6,065
New +$223K
MRNS
43
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$333K 0.15%
+68,900
New +$419K
AVTX icon
44
Avalo Therapeutics
AVTX
$1.08B
$225K 0.1%
156
-349
-69% -$467K
THRX
45
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$179K 0.08%
+32,300
New +$267K
LUMO
46
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$166K 0.07%
+21,520
New +$172K
BLRX
47
BioLineRX
BLRX
$12.1M
$21K 0.01%
417
– –
BCYC
48
Bicycle Therapeutics
BCYC
$303M
– –
-175,000
Closed -$7.68M
FULC icon
49
Fulcrum Therapeutics
FULC
$294M
– –
-136,000
Closed -$3.22M
NCNA
50
NuCana
NCNA
$6.12M
– –
-176
Closed -$878K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2022 Portfolio in Review

As of Q2 2022, Opaleye Management held 56 positions worth $222M, down 31% from $322M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management withdrew a net $21.8M in Q2 2022, closing 9 positions and reducing 17 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $7.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Inhibrx, Inc. Common Stock worth $6.7M.

  • Opaleye Management's largest Q2 2022 buy was Inhibrx, Inc. Common Stock: 590,000 shares worth $6.7M.
  • Opaleye Management added most to TELA Bio in Q2 2022, an estimated $9.68M increase.
  • Opaleye Management's biggest Q2 2022 reduction was Chimerix, Inc., cutting an estimated $14.4M.
  • Opaleye Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $7.68M.
  • Opaleye Management's ten largest holdings make up 59% of its $222M portfolio in Q2 2022.
  • Opaleye Management opened 11 new positions and closed 9 in Q2 2022.
  • Opaleye Management's portfolio value fell 31% quarter-over-quarter to $222M.

Based on Opaleye Management's 13F filing for Q2 2022, filed 15 Aug 2022.